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 2011 EMBO Molecular MedicineHyaline Fibromatosis Syndrome (HFS) is a human genetic disease caused by
mutations in the anthrax toxin receptor 2 (or cmg2) gene, which encodes a
membrane protein thought to be involved in the homeostasis of the extracellular
matrix. Little is known about the structure and function of the protein or the
genotype–phenotype relationship of the disease. Through the analysis of four
patients, we identify three novel mutants and determine their effects at the
cellular level. Altogether, we show that missense mutations that map to the
extracellular von Willebrand domain or the here characterized Ig-like domain of
CMG2 lead to folding defects and thereby to retention of the mutated protein in
the endoplasmic reticulum (ER). Mutations in the Ig-like domain prevent proper
disulphide bond formation and are more efficiently targeted to ER-associated
degradation. Finally, we show that mutant CMG2 can be rescued in fibroblasts of
some patients by treatment with proteasome inhibitors and that CMG2 is
then properly transported to the plasma membrane and signalling competent,
identifying the ER folding and degradation pathway components as promising
drug targets for HFS.al Health Institute,
eiburg, Germany.
usanne Switzerland.
ount Sinai School of
dicine, New York, NY,
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niversitaire Vaudois,
(41) 021 693 9538;INTRODUCTION
Hyaline Fibromatosis Syndrome (HFS) is an autosomal
recessive disorder triggered by mutations in Capillary Morpho-
genesis Gene 2 (cmg2) (Dowling et al, 2003; Hanks et al, 2003;
Stucki et al, 2001). The most severe form of the disease, called
infantile systemic hyalinosis (ISH [MIM 236490]), manifests in
the first weeks of life by painful swelling of the skin and the large
joints as well as oedema of the skin. Although the disease is
named after the accumulation of hyaline material, possibly
collagen VI (Glover et al, 1991; Katagiri et al, 1996; Tanaka et al,
2009), in the skin and other organs (Fayad et al, 1987; Keser
et al, 1999; Landing & Nadorra, 1986), this might be a secondary
consequence of changes in the basal membrane of capillary
vessels (Stucki et al, 2001). Over a time of months to a few years,
affected individuals develop cutaneous tumours over regions ofEMBO Mol Med 3, 208–221 www.embomolmed.org
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perianal region, the alae nasi, the external ears and the nuchal
region on the skull. In addition, patients suffer from flexion
contractures of the joints and osteolytic lesions of the long bones
and distal phalanges (Fayad et al, 1987; Keser et al, 1999) (also
see http://www.orpha.net/). ISH may lead to death in the first 2
years of life because of chronic malabsorption and diarrhoea or
pulmonary infection. Patients suffering from the milder form,
juvenile hyaline fibromatosis (JHF [MIM 228600]), usually do
not present these complications and do not have the infantile
painful phase, but do present cutaneous tumours and debilitat-
ing loss of joint mobility.
The ANTXR2/cmg2 gene encodes for a type I membrane
protein, ANTXR2/CMG2, which harbours an extracellular von
Willebrand A domain (vWA), followed by an uncharacterized
immunoglobulin-like domain (Sun & Collier, 2010), a transmem-
brane domain and finally a 148 residue cytosolic tail (van der Goot
& Young, 2009). The exact function of this protein has not been
established. The vWAwas shown to bind collagen IV and laminin
(Bell et al, 2001), suggesting that CMG2—nomenclature further
used here—is involved in interacting with the extracellular
matrix. In agreement with its initial identification in a gene
profiling studyduring in vitro capillary formation (Bell et al, 2001),
it was recently shown that silencing cmg2 leads to a decrease in
the proliferation of human umbilical vein endothelial cells
(HUVECs) and in the ability to form capillaries in 3D matrices
(Reeves et al, 2009). The best-characterized role of CMG2 is,
however, to be the receptor for the anthrax toxin (Liu et al, 2009;
van der Goot & Young, 2009). CMG2 enables the anthrax toxin to
bind to cells, be internalized and reach the cytosol where it exerts
its toxic function (van der Goot & Young, 2009).
We have recently shown that HFS mutations mapping to the
vWA result in a loss of function due to retention of the protein in
the endoplasmic reticulum (ER; Deuquet et al, 2009). Here, we
have performed a genetic analysis of four new HFS patients and
analysed the consequences of these mutations at the molecular
level. Three of the patients were homo- or heterozygous for
frame-shift mutations in exon 13. We show that these frame-
shift mutations lead to a decrease in the mRNA levels of cmg2,
presumably due to degradation via the nonsense-mediated
mRNA decay (NMD) pathway (Rebbapragada & Lykke-Ander-
sen, 2009). We also identified three novel missense mutations
(p.C39F, p.V310F and p.C315W), which did not affect theTable 1. Clinical features of HFS patients
Age at
genetic
diagnosis
Painful
contractions
in infancy
Ski
hy
Patient 1 (individual II.1, family 1) 2 years þþ
Patient 2 (individual II.2, family 2) 14 years þ
Patient 3 (individual II.2, family 3) 6 weeks þþþ
Patient 4 (individual II.2, family 4) 3 years þþþ
Note that the age of genetic diagnostics differs from the age of symptom onset. For
2 and 3. Patient 3 died before the age of 2, as often for the infantile form of HF
www.embomolmed.org EMBO Mol Med 3, 208–221corresponding mRNA levels but had a severe impact at the
protein level. Residues Val-310 and Cys-315 localize to the Ig-
like domain of CMG2, for which we now provide a model. We
found that mutations in the Ig-like domain affect folding and
disulphide bond formation in the ER, thereby leading to ER
retention. Interestingly, depending on the location of the
mutation (vWA or Ig-like domain), CMG2 was differentially
targeted to the ER-associated degradation (ERAD) pathway.
Using patient-derived fibroblasts, we show that partial rescue of
CMG2 and targeting of a functional protein to the cell surface can
be achieved through treatment with proteasome inhibitors such
asMG132 or bortezomib (BZ; Santa Cruz), a substance currently
in clinical trials (Phuphanich et al, 2010), indicating that these
compounds are potential therapeutic drugs to treat HFS.RESULTS
Description and genetic analysis of the HFS patients
We performed the molecular diagnosis of four patients from
four different families; the neonatal presentation of all index
patients initially raised suspicion of the most severe form of the
disease ISH (see Supplementary Information for more detailed
description of each patient, Table 1). In particular, painful
contractures were the major clinical sign in each case at or
shortly after birth, leading to progressive joint limitations and
delay of motor development; intellectual development was
normal. Typical skin eruptions and mucocutaneous lesions
became apparent early in life. Because of feeding difficulties,
gingivectomy was performed in at least three of the patients.
Despite the similar initial clinical phenotype, the disease
followed a clearly different course for each patient after birth
(Supplementary Information). The most severe disease mani-
festation was observed in Patient 3 who showed the full-blown
picture of ISHwith recurrent, intractable diarrhoea and episodes
of intermittent systemic inflammatory activity (SIRS), causing
acute fatal circulatory failure in infancy. Clinical evidence of
multiorgan involvement was also observed in Patient 4 with the
diagnosis of protein-losing enteropathy at the age of 10 months.
His general condition, however, remained stable under
supportive therapy, and no instance of SIRS or generalized
bacterial infection has occurred up to his current age of 3 years.
In contrast, neither Patient 1 nor Patient 2, who showed themostn eruptions,
gingival
pertrophy
Failure to thrive,
short stature
Intractable,
recurrent
diarrhoea
Systemic
inflammatory
reaction,
recurrent
infections
þþ þþ  
þþ þ  
þ þþþ þþ þþþ
þþ þþþ þþþ 
example, some symptoms were apparent shortly after or at birth for Patients 1,
S.
 2011 EMBO Molecular Medicine 209
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Table 2. HFS mutations analysed in the present work
Patient HFS Zygocity DNA Protein Exon References
1 Juvenile Heterozygote c.116G>T p.C39F 1 This study
c.1074delT p.A359HfsX50 13
2 Juvenile Heterozygote c.928G>T p.V310F 11
c.1073-1074insC p.A359CfsX13 13
3 Infantile Homozygote c.945T>G p.C315W 11
4 Infantile Homozygote c.1073-1074insC p.A359CfsX13 13
5 Infantile Heterozygote c.566T>C p.I189T 7 (Hanks et al, 2003)
c.1073-1074insCC p.A359LfsX51 13
n.a. Juvenile Homozygote c.876-877insCAA p.insQ293 11
n.a. Infantile Homozygote c.652T>C p.C218R 13
n.a. Juvenile Homozygote c.986 T>G p.L329R 12 (Dowling et al, 2003)
n.a. n.a. n.a. c.149 A>C p.D50A 1 (Scobie & Young, 2005)
Nucleotide numbering reflects cDNA numbering withþ1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to the
nomenclature proposed by the Human Genome Variation Society (www.hgvs.org/mutnomen). The initiation codon is codon 1.
n.a.¼not applicable.
210favourable clinical course, developed further complications of
ISH. Our patients thus collectively represent a continuum of
phenotypes associated with HFS, ranging from a fatal multi-
system disorder to a milder, yet disabling, oligosymptomatic
connective tissue disease. We were interested in finding
molecular explanations for these clinical differences with the
aim of identifying genotype–phenotype correlations.
In the least affected families 1 and 2, different compound
heterozygous mutations of cmg2 were detected (Table 2).
Patient 1 carries a c.116G>T transversion predicted to cause aFigure 1. Clinical presentation, pedigrees of HFS families and molecular char
individuals correspond to Table 1. Symbol notations: squares, males; circles, fem
carrier of the nucleotide and predicted amino acid change indicated on top; index p
shown to the right of each pedigree, altered nucleotides are marked in pink in bo
indicate deletions or the site of insertions in exon 13. Inserted nucleotides in pa
sequence given above. All mutations segregated with the disease phenotype, show
parents, and wild-type alleles or heterozygous mutations in unaffected siblings.
 2011 EMBO Molecular Medicinenovel p.C39F amino acid substitution in the amino terminus of
CMG2. In the second allele, a previously described (Hanks et al,
2003) c.1074delT single nucleotide deletion in exon 13 was
found, which modifies the open reading frame by a frame shift
leading to a change in the cytosolic tail of the protein and a
premature stop (Fig 1). Patient 2 carries a missense mutation
resulting in a c.928G>T transversion, leading to substitution of
valine 310 in the ectodomain with a phenylalanine (Fig. 1). In
the second allele, a single base insertion (c.1073_1074insC) was
found again in exon 13, also leading to a frame shift and aacterization.Abridged pedigrees of four HFS families are shown, numbers of
ales; open symbols, unaffected individuals; filled symbols, affected mutation
atients are marked with a red arrow. Electropherograms of index patients are
th reference sequence (top) and actual read (bottom); underlined nucleotides
tients’ sequences are also underlined, predicted changes in the amino acid
ing compound homozygosity or homozygosity in patients, heterozygosity in
EMBO Mol Med 3, 208–221 www.embomolmed.org
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Figure 2. CMG2 protein and mRNA levels in HFS patient fibroblasts.
A. CMG2 was immunoprecipitated from 300mg of cell lysates from
patient-derived fibroblasts and analysed by SDS–PAGE under
non-reducing conditions and Western blotting using the 2F6
anti-hCMG2 antibody.
B. mRNA levels of cmg2 in patient fibroblasts were analysed by quanti-
tative real-time RT-PCR. Patient 5 has been previously characterized and
harbours the I189T mutation in the vWA domain and a frame-shift
mutation in exon 13 (Table 2; Deuquet et al, 2009; Dowling et al, 2003).
The cmg2 mRNA levels in this patient was 5415% of the control
(n¼5). Levels and number of experiments for other patients are
mentioned in the main text. mRNA levels of the unrelated gene RhoA are
shown for comparison. Errors bars represent standard deviations. Paired
t-test analysis between control cells and patient-derived cells was
performed showing that the observed differences are statistically
significant (p< 0.05).
C. Patient-derived fibroblasts were incubated with 10mM MG132 or not
for 16 h. CMG2 was immunoprecipitated from 300mg of cell lysates and
analysed by SDS–PAGE under non-reducing conditions and Western
blotting using the 2F6 anti-hCMG2 antibody.premature stop. Both cases of severe HFS in families 3 and 4
proved to be associated with homozygous mutations. Patient 3
carried a biallelic novel c.945T>G transversion, leading to the
change of cysteine 315 to tryptophan (Fig 1). Patient 4 is
homozygous for the same c.1073_1074insC insertion detected in
Patient 2 (Fig 1). The presence of insertions or deletions in exon
13 for three out of the four patients supports the previous
observation that a GC-rich stretch in exon 13 is a mutational hot
spot (Dowling et al, 2003; El-Kamah et al, 2010; Hanks et al,
2003; Lee et al, 2005).
The HFS mutations lead to drastic reduction of CMG2 protein
levels
Wemade use of a newly generatedmonoclonal antibody (2F6) to
analyse CMG2 in patient-derived fibroblasts. The 2F6 mono-
clonal antibody was obtained by genetic immunization of rats
with a CMG2-expressing plasmid. Characterization of the
antibody indicated that 2F6 specifically binds CMG2 on western
blots of total cell extracts from different cell types, that it
preferentially recognizes the non-reduced form and that it labels
CMG2 by immunofluorescence staining but fails to recognized
the improperly folded ER precursor forms (Supplementary Fig 1).
Based on the mutations identified in the patients, the
following bands were expected to be revealed the patient
fibroblasts: two bands of, respectively, 55 and 40kDa for
heterozygous Patient 1; two bands of 55 and 37kDa for
heterozygous Patient 2, a single 50kDa full-length form for
the homozygous Patient 3, and a single 37 kDa band for
homozygous Patient 4. Surprisingly, CMG2 was undetectable
using the 2F6 antibody in cell extracts of Patients 2–4, weakly
detectable for Patient 1 and as expected readily detectable in
control fibroblasts (Supplementary Fig 2). Enrichment of CMG2
by immunoprecipitation, however, allowed the detection in all
patients but at very low levels (Fig 2A). Note that migration of
full length CMG2 varied between Patients P1–P3 and the control.
As will become apparent below, this is due to the fact that SDS–
PAGE was performed under non-reducing conditions and that
the patient mutations affect disulphide bonding of CMG2.
Low abundance of 2F6 detectable CMG2 protein could be due
to lower mRNA levels in patients. To test this possibility, we
performed quantitative PCR on RNA extracts from patient-
derived fibroblasts. Normalization was performed to three
house-keeping genes (see Materials and Methods Section). In
addition, we analysed an unrelated gene, RhoA, and found that
its mRNA level was identical in all patients (Fig 2B). Levels of
cmg2 mRNA varied greatly amongst patients, with the lowest,
26 17% (n¼ 7), observed for Patient 4, homozygous for the
c.1073-1074insC frame-shift mutation. The two heterozygous
Patients 1 and 2, carrying a nonsense mutation on one allele and
a frame-shift mutation on the other, had intermediate mRNA
levels. These observations suggest that the nonsense mutations
lead to mRNAs recognized by the NMD pathway (Rebbapragada
& Lykke-Andersen, 2009). Interestingly, the mRNAs containing
a premature stop codon varied in susceptibility to the NMD
pathway. Indeed, the cmg2mRNA level of Patient 2, carrying the
c.1073-1074insCmutation, was significantly lower (55 11% of
that of controls, n¼ 7) than that in Patient 1 (76 12%, n¼ 4)www.embomolmed.org EMBO Mol Med 3, 208–221  2011 EMBO Molecular Medicine 211
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212carrying the c.1074delT—even more so considering that both
patients also express a cmg2 mRNA from one allele that is not
prematurely degraded.
While the amount of cmg2 mRNA can explain the very low
level of truncated CMG2 protein in Patient 4, this is not the case
for the other patients suggesting that CMG2 is affected at the
protein level. To test this hypothesis, we investigated whether
inhibition of the proteasome with MG132 would affect CMG2
protein levels in patient cells. MG132 led to an increase in the
CMG2 levels in patient-derived fibroblasts indicating that the
protein was partly degraded by the proteasome. Degradation by
other pathways, such as lysosomes or autophagy, may also
occur since the levels of CMG2 observed for example in Patient 3
upon MG132 treatment by no means match the levels predicted
by the mRNA. Alternatively, CMG2 levels might be increased
but undetectable using the 2F6 antibody. MG132 also led to a
marked increase in CMG2 levels in cells from the control patient.
This could be due to various reasons. Firstly, normal folding of
wild-type (WT) CMG2 could be rather inefficient leading to
significant degradation of newly synthesized protein by the
ERAD pathway andMG132would increase the amount of CMG2
that exits the ER. Secondly, MG132 could have an effect on the
turnover rate of CMG2 at the plasma membrane and lead to an
increase of its half-life.
Model of the CMG2 extracellular Ig-like domain
Our subsequent aim was to understand the mechanisms leading
to the premature degradation of CMG2 mutants in patients. 2011 EMBO Molecular MedicineMutation p.C39F found in Patient 1 maps to the stem of the vWA
domain (Fig 3). Upon expression of the vWA domain in
Escherichia coli, this cysteine forms a disulphide bridge with
Cys-218 (Lacy et al, 2004). The two other mutations, p.V310F
(Patient 2) and p.C315W (Patient 3) map to the Ig-like domain,
the structure of which is unknown. We therefore modelled this
domain using a combination of fold recognition (Biegert et al,
2006; Soding, 2005) and manual modelling (Guex & Peitsch,
1997). The model shows an Ig-like fold (Fig 3B) where, quite
remarkably, four cysteine residues are positioned in a manner
compatible with the formation of two disulphide bridges: C230-
C315 and C255-C279. In further support of the model, the two
potential N-glycosylation sites, at least one of which is known to
be modified (Deuquet et al, 2009), localize to the solvent
exposed surface of the domain.
We next sought experimental evidence for the existence of the
predicted disulphide bonds. Single cysteine to alaninemutations
were generated for each of the seven ectodomain cysteine
residues (Fig 3B) as well as double cysteine mutants
corresponding to the predicted pairs. Expression was analysed
in two cell lines, human Hela cells and Chinese Hamster Ovary
(CHO) cells, since these two cell types vary in their protein
glycosylation and/or folding capacity, leading to differences in
the CMG2 migration pattern on SDS gels (Deuquet et al, 2009).
In CHO cells, CMG2 shows a very distinct pattern with a single
sharp band, corresponding to the glycosylated ER precursor
form, and a broad highermolecular weight smear corresponding
to mature CMG2, in which the N-linked sugars have beenFigure 3. Model of the ectodomain of CMG2.
A. Basic representation of the CMG2 protein and its
domains, highlighting the positions of the seven
cysteines and HFS mutations analysed in this
study.
B. Structural model of the extracellular domains of
CMG2. The vWA domain has been taken from the
crystal structure 1tzn, chain ‘a’, and the predicted
Ig-like model (this work) has been grafted onto
the crystal structure of the vWA domain (1tzn,
chain a). To better show the overall fold, the
successive secondary structure elements
each have a distinct colour from dark-blue
(N-terminal) to red (C-terminal). Cysteines
participating in predicted disulphide bridges are
marked as black spheres.
EMBO Mol Med 3, 208–221 www.embomolmed.org
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(Deuquet et al, 2009). Hela cells have the advantage of being
easily transfected at high rates; however, the migration pattern
of CMG2 in these cells does not show a clear boundary between
the precursor and mature forms, although both are present
(Deuquet et al, 2009).
Single mutants of the vWA domain cysteines did not
drastically affect the migration pattern, i.e. both the precursor
and the mature form were observed (Fig 4A), indicating that a
significant proportion of the protein was able to exit the ER.
Immunofluorescence analysis and surface biotinylation experi-
ments further showed that mutation of Cys-39 or Cys-218 to
alanine does not significantly affect targeting of CMG2 to the cell
surface (Fig 4B and E).
In marked contrast, mutation of any cysteines in the Ig-like
domain led to an almost complete disappearance of mature
CMG2 (Fig 4C) and rendered the protein fully sensitive to
Endoglycosidase H (EndoH; Fig 4D), an enzyme that can only
remove non-complex oligosaccharides, suggesting that trans-
port of CMG2 to the Golgi was impaired. Immunofluorescence
analysis of the mutants revealed a typical reticulate ER staining
(illustrated in Fig 4E for C315A).
To establish the exact disulphide pairing, extracts from cells
expressing the single cysteine mutants were treated with N-
ethylmaleimide (NEM) to block any free cysteines and analysed
by SDS–PAGE under non-reducing conditions. Migration of WT
CMG2 was very similar to that observed under reducing
conditions (Fig 5A). A higher 114 kDa molecular weight form,
corresponding to a dimer (see below and Fig 5B), was, however,
observed for the two single, C39A and C218A, cysteine mutants
(Fig 5A and C). The presence of this disulphide-linked dimer
implies that, upon the single cysteine to alanine mutation,
another cysteine in the protein became available for inter-
molecular disulphide bond formation and thus, that in the WT
protein, these two cysteines are bonded. The absence of the
dimeric band for the double C39A–C218A mutant confirms the
pairing of these residues.
The pattern for the Ig-like domain single cysteine mutants
wasmore complex, with higher order complexes consistent with
CMG2 trimers and tetramers (Fig 5A). The presence of higher
order complexes for all single cysteine mutants not only
indicates that all four Ig-like domain cysteines are involved in
disulphide bond formation but that more than one cysteinemust
have become available for inter-molecular disulphide bond
formation. This in turn implies that disruption of one bridge in
the Ig-like domain impairs formation of the other.
The migration pattern of the C230A–C315A double mutant
was simpler than that of the two corresponding single mutants
confirming disulphide bonding between these two residues in
the WT protein (Fig 5D). A disulphide-linked dimer was,
however, still observed revealing the presence of one free
cysteine and suggesting that the remaining Cys-255–Cys-279
bridge failed to form. The free cysteine in the C230A–C315A
mutant is likely to be Cys-255, since Cys-279, even in a
misfolded protein, probably resides in the core of the domain
and is thus inaccessible for inter-molecular disulphide bond
formation. The migration pattern of the last C255A–C279Awww.embomolmed.org EMBO Mol Med 3, 208–221double mutant remained as complex as that of the correspond-
ing single mutants, indicating that the two remaining cysteines,
Cys-230 and Cys-279, both of which are exposed, became
available for inter-molecular disulphide bridge formation.
Altogether, these observations determine the identity of the
three-disulphide bridges in the CMG2 ectodomain and show
that, while the bridge that caps the vWA domain is not essential
for passing the quality control leading to ER exit, the two bridges
in the Ig-like domain are. The ER retention phenotype could not
be rescued by mutating all Ig-like domain cysteines (Fig 5E)
indicating that the disulphide bridges are essential for proper
folding/stability of CMG2.
The above-mentioned conclusion that the 114 kDa com-
plexes observed for CMG2 cysteine mutants correspond to
covalent dimers is based on the following experiments. Cells
were co-transfected with C218A harbouring an HA tag and
C218A harbouring a V5 tag. Immunoprecipitation was
performed using an antibody against the HA-tag followed by
Western blotting, under non-reducing conditions, with an
antibody against the V5 tag. A V5-positive band was observed at
114 kDa, while no band was observed as expected at 55 kDa
corresponding to the monomer. The monomer was, however,
detected with the HA antibody. Similar co-transfection experi-
ments were performed for the WT protein and for the C230A
mutant. A far more pronounced co-immunoprecipitation was
observed with the C230A mutant, consistent with the higher
abundance of complexes of different sizes, while no co-
immunoprecipitation was observed for the WT proteins.
C39F and C218R HFS mutations affect folding of
the ectodomain
We next investigated whether the HFS mutations involving
cysteine residues had similar effects as those observed above for
cysteine to alanine mutations. We included in this analysis the
previously described p.C218R mutation found in a homozygous
HFS patient (Table 2; Hanks et al, 2003).
Upon expression of C39F or C218R CMG2, both the mature
and the ER precursor forms were observed under reducing
conditions (Fig 6A), but the relative abundance of the precursor
was higher than for theWT protein, as even more apparent after
EndoH treatment (Fig 6B). Partial ER retention was confirmed
by immunofluorescence analysis, where we could detect both
plasma membrane and ER staining, as particularly indicated by
the staining of the nuclear membrane (illustrated for C39F in
Fig 6C).
Moreover, analysis of C39F and C218R CMG2 by non-reducing
SDS–PAGE showed that, in contrast to the corresponding alanine
mutants, which only formed dimers, patient mutations led to the
formation of higher order complexes (Fig 6D) which were not
seen under reducing conditions (Supplementary Fig 4A). This
reveals the availability of more than one cysteine to inter-
molecular disulphide bonding. In patients, the presence of a
bulky phenylalanine residue at position 39 or a long charged
arginine side chain at position 218 is therefore significantly more
disruptive thanmerely preventing formation of the 39-218 bridge.
Folding of the vWA domain was, however, not significantly
impaired as revealed by the ability of the mutant CMG2 proteins 2011 EMBO Molecular Medicine 213
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Figure 4. Mutations of Ig-like domain cysteines
lead to ER retention of CMG2.
A,C. HeLa or CHO cells were transfected for 48 h
with WT or mutant CMG2-V5 constructs. Cell
extracts were analysed by SDS–PAGE and
Western blotting with an anti-V5 antibody.
B. HeLa cells were transfected for 48 h with WT or
mutant CMG2-V5 cDNAs. Confluent cells were
pulsed with [35S]-methionine and subsequently
incubated with 0.2 mg/ml NHS-SS-biotin. Bio-
tinylated CMG2 proteins and expression levels
were quantified using the Typhoon scanner. For
each experiment, biotinylated CMG2 values
were normalized to the synthesis levels and
expressed as a percentage of WT. Error bars
represent the standard deviation (n¼ 3).
D. CHO cell lysates were submitted to immuno-
precipitation with an anti-V5 antibody, treated
with or without EndoH and analysed by
SDS–PAGE and Western blotting with an
anti-V5 antibody.
E. HeLa cells were transfected with WT or mutant
CMG2-V5 cDNA for 24 h prior to fixation and
permeabilization and labelling with anti-V5
monoclonal as well as anti-calnexin polyclonal
antibodies. The inserts illustrate an enlarge-
ment of a specific region. Bar: 10mm.
214to bind the anthrax protective antigent (PA) in cell lysates
(Fig 6E).WT and the previously analysed ER retained HFS L329R
mutant (Table 2) were used as positive controls (Deuquet et al,
2009), while D50A, mutated in the vWA ligand binding site
(Scobie & Young, 2006) and L45P affected in vWAdomain folding
(Deuquet et al, 2009), were used as a negative control.
Finally, surface biotinylation experiments showed that plasma
membrane targeting of C39F and C218Rwas impaired (Fig 6F) as
we previously reported for the C218R mutation (Deuquet et al,
2009). When comparing Figs 4B and 6F, it is again apparent that
the mutations found in the patients have a more severe effect on
transport than cysteine to alanine mutations.
Ig-like domain HFS mutations lead to aberrant disulphide
bond formation and severe ER retention
We next analysed the effects of the mutations observed in
Patients 2 and 3 as well as of a previously reported mutation in
the Ig-like domain that leads to the insertion of a glutamine
residue at position 293 (p.InsQ293) (Hanks et al, 2003). Upon 2011 EMBO Molecular Medicineexpression in CHO cells, V310F, C315W, and InsQ293 migrated
as essentially a single (Fig 7A), EndoH sensitive (Fig 7B) band.
Immunofluorescence analysis showed that the mutant proteins
were retained in the ER (Fig 7C). Non-reducing SDS–PAGE
revealed that these mutants efficiently formed high order inter-
molecular disulphide bonded complexes (Fig 7D) indicative of
the availability of two ormore cysteine residues. Finally, surface
biotinylation analysis showed that only a small fraction reached
the plasma membrane (Fig 7E). ER retention of CMG2 could not
be alleviated by the mere removal of the mutation-sensitive Ig-
like domain as indicated by the analysis of an isoform of CMG2
(isoform 2, Uniprot Ref P58335-2), which lacks exons 8–11
encoding the six last residues of the vWA domain—including
Cys-218—as well as the entire Ig-like domain. CMG2 isoform 2
indeed failed to reach the plasma membrane (Fig 7E) and
localizes to the ER as demonstrated by immunofluorescence
(Bell et al, 2001).
That HFS mutations in the Ig-like domain affect folding is
supported by analysis of the Ig-like domain model: Val-293 isEMBO Mol Med 3, 208–221 www.embomolmed.org
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Figure 5. CMG2 cysteine mutants form higher
order homo-complexes.
A,C-E. CHO cells were transfected for 48 h with WT
or mutants CMG2-V5 constructs. Cell lysates
were subjected to immunoprecipitation with
an anti-V5 antibody and analysed by
SDS–PAGE— under reducing or non-reducing
conditions — and Western blotting with an
anti-V5 antibody.
B. HeLa cells were co-transfected for 48 h with
mutant CMG2-V5 or CMG2-HA constructs.
Cell lysates were subjected to immunopre-
cipitation with an anti-HA antibody and
analysed by SDS–PAGE under non-reducing
(WB: V5) and reducing (WB: HA) conditions
and Western blotting with anti-V5 or anti-HA
antibodies.predicted to be located in the middle of a b-strand. Inserting a
residue at this position would lead to an out-of-register b-strand,
leading to the exposure of initially buried hydrophobic residues,
a change expected to have major impact on folding. Val-310
makes a direct hydrophobic contact with Val-293, in the core of
the Ig-like domain. Introduction of a bulkier side chain—
phenylalanine versus valine—should not be easily accommo-
dated by the structure.
The CMG2 vWA and Ig-like domains are two independent
folding units
The above described observations show that HSF mutations in
the Ig-like domain affect folding of this domain. As readout for
proper vWA domain folding, we investigated whether the
insQ293, V310F, and C315W CMG2mutants are able to bind the
anthrax PA. PA binding was again performed in cell lysates as
above (Fig 6E). Ig-like domain mutants were competent of PA
binding (Fig 7F), indicating that even if the Ig-like domain did
not fold properly, the vWA domain did.
To further evaluate the ability of the vWA and Ig-like domains
to fold independently, we investigated whether previously
analysed vWA domain HFSmutations (Deuquet et al, 2009) lead
to the formation of inter-molecular disulphide bond formation,
used as an indication of defect Ig-like domain folding. Dimeric
forms were observed for the previously described L45P, G105D,www.embomolmed.org EMBO Mol Med 3, 208–221and I189T mutations, but bands corresponding to trimers and
tetramers were absent, suggesting that these mutations affected
the formation of the Cys39–Cys218 bond (Supplementary
Fig 4B), but not those in the Ig-like domain.
Altogether, these observations indicate that the vWA and Ig-
like domains constitute independent folding units. This is
important since it indicates that if Ig-like domain HFS CMG2
mutants were rescued from ER retention, they would be
competent for ligand binding and likely functional, and thus that
the ER folding/quality control and ERAD components are
potential therapeutic targets for HFS.
Proteasome inhibitors can rescue CMG2 in HFS patient cells
In view of a possible therapeutic intervention, we tested the
effect of BZ, also known as Velcade, the first therapeutic
proteasome inhibitor tested in humans (Adams & Kauffman,
2004), on CMG2 levels in HFS patient fibroblasts. The effect of
BZ (Fig 8A) was very similar to that of MG132 (Fig 2C) with an
increase in the levels of CMG2 for all patients including control.
The highest levels of CMG2 were reached for Patient 1. We
wondered whether this was because Patient 1 harbours a
mutation in the vWA domain, while the missense mutations in
Patients 2 and 3 map to the Ig-like domain. To address this
possibility, we analysed CMG2 in fibroblasts from a previously
described patient (Patient 5) heterozygous for the p.I189T 2011 EMBO Molecular Medicine 215
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Figure 6. C39F and C218R HFS mutations lead to inter-disulphide bond
formation and ER retention.
A,D. CHO cells were transfected for 48 h with WT or mutants CMG2-V5
constructs. Cell lysates were subjected to immunoprecipitation with an
anti-V5 antibody. Samples were analysed by SDS–PAGE— under
reducing or non-reducing conditions —and Western blotting with an
anti-V5 antibody.
B. CHO cell lysates were subjected to immunoprecipitation with an anti-V5
antibody, treated with or without EndoH enzyme and analysed by
SDS–PAGE and Western blotting with an anti-V5 antibody.
C. HeLa cells were transfected with WT or mutant CMG2-V5 cDNA for 24 h
prior to fixation and permeabilization, and labelling with anti-V5
monoclonal and anti-calnexin polyclonal antibodies. Bar: 10mm.
E. CHO cells were transiently transfected with WT or mutant CMG2-V5
cDNA. Cells were lysed in immunoprecipitation buffer and 1mg/ml of PA
was added in the buffer for 1 h at 48C. After immunoprecipitation using
an antibody against the V5 tag, samples were analysed by SDS–PAGE
followed by Western blotting against PA or the V5 tag.
F. HeLa cells were transfected for 48 h with WT or mutant CMG2-V5 cDNA.
Surface biotinylation was performed as in 4B. Error bars represent the
standard deviation (n¼ 3). Asterisks represent significant difference
with respect to WT (p< 0.05).
Figure 7. Various HFS mutations in the CMG2 Ig-like domain lead to inter-
disulphide bond formation and ER retention.
A,D. CHO cells were transfected for 48 h with WT or mutants CMG2-V5 con-
structs. Cell lysates were subjected to immunoprecipitation with an anti-V5
antibody. Samples were analysed by SDS–PAGE—under reducing (A) or non-
reducing conditions (D)—and Western blotting with an anti-V5 antibody.
B. CHO cell lysates were subjected to immunoprecipitation with an anti-V5
antibody, treated with or without EndoH and analysed by SDS–PAGE and
Western blotting with an anti-V5 antibody.
C. HeLa cells were transfected with mutant CMG2-V5 cDNAs for 24 h prior
to fixation and permeabilization, and labelling with anti-V5 antibodies.
E. CHO cells were transiently transfected with WT or mutant CMG2-V5
cDNA. Cells were lysed in immunoprecipitation buffer and 1mg/ml of PA
was added in the buffer for 1 h at 48C. After immunoprecipitation using
an antibody against the V5 tag, samples were analysed by SDS–PAGE
followed by Western blotting against PA or the V5 tag.
F. HeLa cells were transfected for 48 h with WT or mutant CMG2-V5 cDNA.
Surface biotinylation was performed as described in 4B. Error bars
represent the standard deviation (n¼ 3). Asterisks represent significant
difference with respect to WT (p<0.05).
216mutation in the vWA domain and a frame-shift mutation in exon
13 (Deuquet et al, 2009; Dowling et al, 2003). We have
previously shown that the I189T mutation does not affect the
structure of the vWA domain per se, but slows down folding of 2011 EMBO Molecular Medicinethe domain as to render CMG2 detectable by the ER quality
control in the cellular context (Deuquet et al, 2009). As shown in
Fig 2B, the mRNA levels of CMG2 in Patient 5 were very similar
to that found in Patient 2. In agreement with our hypothesis, full-EMBO Mol Med 3, 208–221 www.embomolmed.org
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Figure 8. Rescue of CMG2 cell surface expression and function in HFS
patient cells upon exposure to proteasome inhibitors.
A. Patient-derived fibroblasts were incubated with 10mM of BZ or not for
16 h. CMG2 was immunoprecipitated using the goat anti-human CMG2
antibody from 300mg of cell lysates and analysed by SDS–PAGE under non-
reducing conditions and Western blotting using the 2F6 anti-hCMG2
antibody.
B. Fibroblasts derived from Patients 1, 2 and 5 and control cells were
incubated with 10mM BZ or not for 16 h and subsequently incubated with
0.2 mg/ml NHS-SS-biotin. Cell lysates (300mg of total proteins) were
subjected to immunoprecipitation with streptavidin–agarose beads and
analysed by SDS–PAGE and Western blotting probed with anti-hCMG2,
anti-calnexin and anti-hTransferin receptor antibodies.  indicates
unspecific band recognized by the 2F6 antibody after surface biotinylation
and immunoprecipitation. This band is also observed for Patient 4
fibroblasts that express undetectable levels of CMG2. While calnexin (Cnx)
was absent in these immunoprecipitations, it was readily detected in cell
extracts (Supplementary Fig 4E). Under non-reducing conditions, human
transferrin receptor (hTfR) migrates as a covalent dimer.
C. Fibroblasts derived from Patient 1 and control cells were incubated with
10mM BZ for 16 h and subsequently incubated with anthrax PA at a
500 ng/mL final concentration. After different time points, cell lysates were
immunoprecipitated with an anti-hCMG2 antibody. Samples were ana-
lysed by SDS–PAGE under reducing or non-reducing conditions and
Western blotting with an anti-hCMG2, an anti-ubiquitin, and anti-PA
antibodies.length CMG2 was detectable in fibroblasts from Patient 5, albeit
at lower levels than for Patient 1 (Fig 8A) and this level was
increased upon treatment with either MG132 (Supplementary
Fig 4C) or BZ (Fig 8A) but to a lesser extent than for Patient 1.
We next analysed plasma membrane targeting of rescued
CMG2 by surface biotinylation of control fibroblasts and
fibroblasts from Patient 1, 2, and 5. Patients 3 and 4 were not
included in this analysis because the sensitivity of surface
biotinilyation would not allow the detection of the low levels of
CMG2 observed in these patients even after treatment with
proteasome inhibitors. Equal amounts of proteinswere submitted
to precipitation with streptavidin beads. Treatment with MG132
(Supplementary Fig 4D) or BZ (Fig 8B, Supplementary Fig 4E) led
to an increase in the amount of CMG2 detectable at the plasma
membrane both for WT and mutant proteins, albeit to differentwww.embomolmed.org EMBO Mol Med 3, 208–221extents. This indicates that inhibition of the proteasome not only
rescued mutant CMG2 from degradation but allowed it to exit the
ER and reach the plasma membrane. The increase in WT protein
at the cell surface in BZ treated fibroblasts is likely due to both an
increase in ER exit and a reduction in surface removal as
discussed above for MG132 treatment.
We have previously shown, using anthrax PA as a ligand, that
CMG2 undergoes ligand-triggered endocytosis (van der Goot &
Young, 2009) and that this requires ligand-induced signalling
via CMG2 (Abrami et al, 2010b). More specifically, we have
shown that the toxin bound to the extracellular domain of CMG2
triggers ubiquitination on the cytosolic tail and that ubiquinita-
tion is required for efficient endocytosis of the ligand-receptor
complex via clathrin-coated pits (Abrami et al, 2003, 2006,
2010a). As evidence for the ability of CMG2 to signal, we have
monitored CMG2 endocytosis in BZ-treated Patient 1 fibroblasts
upon exposure to anthrax PA as a proof of concept. PA led to
rapid degradation of CMG2 showing that the toxin led to
receptor endocytosis and targeting to lysosomes (Fig 8C).
Moreover, PA triggered ubiquitination of CMG2 not only in BZ-
treated control but also patient fibroblasts (Fig 8C), revealing the
ability of CMG2 to signal. This ubiquination signal was weakly
detectable for the WT protein in the absence of BZ treatment, as
expected due to the lower levels of CMG2, and undetectable for
the mutant protein (Supplementary Fig 4F) consistent with the
absence of surface CMG2 in Patient 1 cells.DISCUSSION
The severity of HFS ranges from being lethal during early
childhood to chronic and highly debilitating at a later age. While 2011 EMBO Molecular Medicine 217
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218the exact function of CMG2 remains to be unravelled, our studies
show that the majority of the HFS mutations lead to loss of
function due either to the instability of the CMG2messenger—in
the case of frame-shift mutations in exon 13—or to improper
folding of the ectodomain of the protein in the ER followed by ER
retention and degradation. We find that CMG2 protein harbour-
ing mutations in the ectodomain can partially be rescued through
treatment with proteasome inhibitors. This rescue, which not
only leads to partial recovery in terms of protein levels but also
plasma membrane targeting of a functional protein, might to be
more efficient for mutations that map to the vWA domain than
mutations mapping to the Ig-like domain, highlighting the
importance of in-depth genotype–phenotype analysis for poten-
tial personalized therapeutic treatment.
CMG2 structure, ER folding, quality control and degradation
Our work provides additional understanding of the structure of
the CMG2 ectodomain. Following the vWA domain, CMG2
harbours an Ig-like domain that is well conserved in different
species (47–82% identity with zebrafish and bovine, respec-
tively) as well as in the homologous protein TEM8 (46%
identity; Supplementary Fig 3A; van der Goot & Young, 2009).
We previously found that, with the exception of the p.T118K
mutation (Lindvall et al, 2008), which affects the ligand binding
MIDAS motif (Scobie & Young, 2006), HFS mutations that map
to the vWA domain lead to slow or aberrant folding in the ER
and thus recognition by the ER quality control (Deuquet et al,
2009). This, however, does not lead to complete degradation by
ERAD as we show here using patient fibroblasts. The retention
of CMG2 in the ER in the absence of complete degradation
provides a window of opportunity for therapeutic treatments
that would promote ER exit.
The N- and C-termini of the vWA domain are bridged by a
disulphide bond. While formation of this bond probably occurs
in the ER, its formation is not a prerequisite for ER exit. In
contrast, the Ig-domain contains two disulphide bridges,
formation of both of which is essential for ER exit. It has been
shown that ER folding is generally under thermodynamic rather
than kinetic control (Sekijima et al, 2005; Wiseman et al, 2007).
Therefore, it is likely that disulphide bond formation in the Ig-
like domain has a strongly stabilizing effect that drives the
folding reaction forward. Improper folding of the Ig-like domain
leads to the formation of inter-disulphide-linked CMG2 com-
plexes that are presumably recognized by the ER quality control
system and efficiently targeted to the ERAD pathway. As a
consequence, the CMG2 protein is undetectable using our 2F6
antibody in the cells from patients harbouring mutations in the
Ig-like domain.
Treatment with proteasome inhibitors
Our study shows that HFS missense mutations in the
ectodomain lead to post-translational protein degradation. We
hypothesize that the loss of CMG2 function is the cause of the
disease. Considering that the HFS missense mutations lead to
CMG2 ER retention, an alternative possibility could have been
that thesemutations trigger the unfolded protein response (UPR;
Ron & Walter, 2007), which in turn would cause the disease. 2011 EMBO Molecular MedicineThis latter explanation however seems unlikely in light of
Patient 4, who shows all classical HFS symptoms. In this patient,
the loss of CMG2 is due to excessive degradation of the cmg2
mRNA. The C-terminally truncated CMG2 that is produced—at
very low levels—is properly targeted to the plasma membrane
(Liu et al, 2007) and thus would not trigger any UPR. Similarly,
the p.T118K mutation, which was reported for a homozygous
HFS patient (Lindvall et al, 2008) and is defective in ligand
binding (Scobie & Young, 2006), does not show any folding
defect and is not expected to trigger the UPR.
Our strategy was therefore to attempt rescuing CMG2 from
ERAD using proteasome inhibitors. We found that MG132—
routinely used in tissue culture studies—as well as its derivative
BZ—used in a number of clinical trials—allow the partial rescue
of CMG2 protein in patient cells. Interestingly, the level of rescue
correlates with the severity of the disease: rescue is extremely
weak in patients showing typical infantile symptoms such as
recurrent diarrhoea in early childhood (Patients 3 and 4), while
rescue is observed for Patients 1, 2 and 5 who show a milder
form of the disease (the severity of the disease cannot be
compared between these patients due to the differences in
medical care received during early childhood).
More in depth studies on cells from Patient 1 showed that,
upon treatment with BZ, CMG2 protein levels could be restored
to approximate control levels, that the protein was properly
targeted to the plasma membrane, and that it was signalling
competent. It is important to note that a full rescue of CMG2
protein levels is unlikely to be necessary since individuals with
only one mutated cmg2 allele do not suffer from HFS indicating
that an 50% protein level is sufficient. This is further
supported by our findings that silencing cmg2mRNA expression
to 60% had no effect whatsoever on the gene expression
profile of HUVEC (not shown). Altogether, our study shows that
drugs affecting the proteasome are promising therapeutics to
treat HFS patients, especially those harbouring missense
mutations in exons 1–7.MATERIALS AND METHODS
Subjects and genetic analysis for mutation detection
All patients were ascertained by physician-initiated referral.
We collected blood and isolated DNA from cases diagnosed at the
children’s hospital of Freiburg University in accordance with the
Declaration of Helsinki principles, specifically under a protocol
approved by the ethics review board Baden-Wu¨rttemberg, or from
cases referred through the European skeletal dysplasia network
(ESDN). Informed consent was obtained for all subjects, each family
member was assessed by clinical criteria. Control samples and
primary cells were obtained from ancestry-, sex- and age-matched
healthy individuals.
For the genomic analysis and mutation detection, exons including
intron–exon boundaries of ANTXR2 were amplified by PCR using
standard protocols published previously (Hanks et al, 2003).
Sequences of amplified PCR products were determined on an
ABI3130xl capillary sequencer (Applied Biosystems). Sequence data
were processed using ABI software and analysed using SequencherEMBO Mol Med 3, 208–221 www.embomolmed.org
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The paper explained
PROBLEM:
HFS is a human genetic disease caused by mutations in the
anthrax toxin receptor 2 (or cmg2) gene, which encodes a
membrane protein thought to be involved in the homeostasis of
the extracellular matrix. The most severe form of the disease
manifests in the first weeks of life by painful swelling of the skin
and the large joints and oedema of the skin as well as chronic
malabsorption and diarrhoea or pulmonary infection which may
lead to death in the first 2 years of life. Patients suffering from the
milder form usually do not present these complications but do
present cutaneous tumours and debilitating loss of joint
mobility. Little is known about the genotype–phenotype
correlation.
RESULTS:
Using patient cells and in vitro approaches, we show that there is
a drastic decrease of the CMG2 protein in the four patients
analysed in this study, which harbour novel mutations. These
observations suggest that the disease is caused by a loss of CMG2
function. We find that in three of the four patients, the protein is
prematurely degraded, while in the fourth patient, it is the cmg2
mRNA, which is prematurely degraded. We show that premature
protein degradation is due to improper folding of CMG2 in the ER,
which is, therefore, recognized by the ER quality control and
targeted for degradation by the proteasome. Finally, we show
that proteasome inhibitors can partly rescue the CMG2 protein,
which then properly folds, is released from the ER, and targeted
to the cell surface where it is competent for signalling.
IMPACT:
This work illustrates that the proteasome, and presumably other
components of the ER degradation system, are potential
therapeutic targets for HFS.(Genecodes). We compared amplicon sequences against the cDNA
reference sequence for ANTXR2 (ENST00000403729) with nucleotide
numbering starting from the first transcribed nucleotide of the
reference sequence. Mutations and polymorphisms were confirmed in
two independently amplified PCR products using bidirectional
sequencing.
For the allele frequency analysis, in 120 normal controls of European
descent, exons 1 and 11 of ANTXR2 were amplified and sequenced
unidirectionally to screen for HFS-associated mutations. An additional
105 controls of Turkish decent was screened for the ANTXR2
c.945T>G mutation, detected in family 3. No mutations were found
in the non-affected patients.
Sequence alignments and modelling
For the multiple sequence alignment the following genes were used:
P58335, Q6DFX2, Q00IM8, Q08DG9, A4QP34 for CMG2 and Q9H6X2,
Q9CZ52, Q0PMD2, XP_873063.2, XP_692362.2 for TEM8. The
computer program MUSCLE (Edgar, 2004) was used to generate the
alignment, and Jalview (Waterhouse et al, 2009) to visualize it.
We used HHpred (Biegert et al, 2006; Soding, 2005) to predict the fold
of the 107 residues of the CMG2 protein, located between the vWA
domain and the transmembrane domain. The two best hits identified
were 2CXK (pval 1.3E-06) and 2UZX (pval¼2.1E-03), clearly identify-
ing an Ig-like fold. Phyre (Bennett-Lovsey et al, 2008)] also predicted an
Ig-like fold. We then used CDD (Marchler-Bauer et al, 2009) to gather a
representative set of structures containing an Ig-like fold domain (2cxk,
2as5, 1vkx, 1imh, 1ttu, 1cyg, 1clu, 7cgt, 1qhp, 1uad, 2uzx, 1gji, 2v2t,
1a3q, 2yrp, 1kcl and 1nfk), which were structurally superposed using
Swiss-PdbViewer (Guex & Peitsch, 1997). We then manually aligned
CMG2 onto this framework using a combination of the predictions
returned by HHpred and Phyre (Supplementary Fig 3B). Finally, the
predicted Ig-like model has been manually grafted onto the crystal
structure of the vWA domain (pdb entry 1tzn, chain ‘a’).www.embomolmed.org EMBO Mol Med 3, 208–221Reagents, proteasome inhibition and EndoH treatment
The anti-human CMG2 monoclonal antibody 2F6 was obtained by
genetic immunization of rats with an hCMG2 construct (Genovac,
Germany); polyclonal goat anti human CMG2 antibodies were from
R&D (Ref. AF2940), PA of anthrax toxin, anti-PA and anti-CMG2
antibodies were provided from the Leppla laboratory; goat anti-
human CMG2 antibody was from R&D Systems; anti-HA-HRP
antibody, anti-HA beads were from Roche (Basel, Switzerland); anti
human-transferin receptor from Invitrogen (Carlsbad, CA); protein G-
agarose-conjugated beads were from GE Healthcare; anti-V5 antibody
was from Invitrogen; streptavidin–agarose conjugated beads from
Sigma–Aldrich (St. Louis, MO); anti-ubiquitin antibody from Santa
Cruz; HRP secondary antibodies from Pierce Chemical Co. (Rockford,
IL); Alexa-conjugated secondary antibodies from Jackson Immunor-
esearch. The proteasome inhibitors—MG132 was from Sigma, BZ—
were used at a final concentration of 10mM for 16 h in complete
medium. Treatments with EndoH were performed as previously
described (Abrami et al, 2006).
Cells, plasmids, transfection and real-time PCR
Primary fibroblasts derived from patient biopsies were grown in
DMEM medium complemented with fetal bovine serum and penicillin/
streptavidin, counting at 1.5106 cells in a 10 cm diameter dish, for
24 h. HeLa and anthrax toxin receptor-deficient CHO (here designated
as CHO) cells were grown as described (Abrami et al, 2006, 2004). The
human CMG2 (isoform 4, Swiss-Prot P58335-4, GenBank
AK091721.1) gene, tagged with a V5 epitope at the C-terminus, was
cloned in the pcDNA3.1/V5-HIS-TOPO expression vector (Invitrogen).
Mutations were generated using the QuickChange Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA). Transfections were
performed with Fugene (Roche Diagnostics Corporation).
For real-time PCR, RNA was extracted from a confluent six-well dish of
patient fibroblasts using commercial RNA easy mini extraction kits 2011 EMBO Molecular Medicine 219
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220(Quiagen). RNA was quantified by spectrometry and 1mg was used for
reverse transcription using hexanucleotides (Roche). A 1:40 dilution
of the cDNA was used to perform the real-time PCR using the Sybr
Green reagent (Roche). mRNA levels were normalized using three
house-keeping genes: TATA-binding protein (TBP), b-microglobulin and
b-glucoronidase (GUS).
Immunofluorescence
HeLa cells were fixed with paraformaldehyde and permeabilized with
1% Triton and labelled with an anti-V5 monoclonal and anti-calnexin
polyclonal antibodies followed by the appropriate secondary anti-
bodies. Images were acquired using a Plan-Apochromat 100/1.4 oil
emersion objective on an Axiovert 200M (Carl Zeiss Microimaging,
Thornwood, NY), equipped with Axiocam camera using the Axiovision
acquisition software. The Adobe Photoshop software was used to
prepare the figures.
Surface biotinylation, metabolic labelling and
immunoprecipitation
For immunoprecipitation, confluent cells were washed three times
with PBS. Cells were lysed by incubation for 30min at 48C with 0.5%
NP-40, 500mM Tris–HCl, pH 7.4, 20mM EDTA, 10mM NaF, 30mM
sodium pyrophosphate decahydrate, 2mM benzamidine, 1mM PMSF,
1mM NEM and a cocktail of protease inhibitors (Roche). Cells lysates
were incubated over-night at 48C with anti-V5 or goat anti-human
CMG2 antibodies and protein G sepharose beads. For CMG2 detection,
western blots were revealed using the rat monoclonal 2F6 anti human
CMG2 antibody.
For metabolic labelling, HeLa cells were transfected for 48 h with
CMG2 cDNAs, starved with methionine/cysteine-free medium, incu-
bated for a 20min pulse at 378C with 50mCi/mL [35S] methionine
(Hartman Analytics) and then incubated for 10min at 378C in
complete medium with a 10-fold excess of non-radioactive methio-
nine and cysteine.
For surface biotinylation, CMG2 transfected Hela cells or patient-
derived fibroblasts were incubated with 0.2mg/ml NHS-SS-biotin
(Pierce) in PBS for 30min at 48C and washed with sterile PBS
containing 100mM NH4Cl. Lysates were immunoprecipitated with
anti-streptavidin coated agarose-beads, or with anti-V5 or anti-CMG2
and protein G sepharose beads. After SDS–PAGE and Western blotting
against the V5 tag or endogenous CMG2 protein, biotinylated CMG2
proteins and expression level were quantified with Image Quant TL
2005/Typhoon software (GE Healthcare). The signal of biotinylated
CMG2 was normalized to the level of CMG2 synthesis as determined
by metabolic labelling. Expression of CMG2 mutants at the cell surface
was normalized to that of the WT protein.Author contributions
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